Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
What is the competitive landscape for TEVA BRANDED PHARM, and what generic alternatives to TEVA BRANDED PHARM drugs are available?
TEVA BRANDED PHARM has twenty-five approved drugs.| Patents: | 46 |
| Tradenames: | 24 |
| Ingredients: | 14 |
| NDAs: | 25 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
levonorgestrel; ethinyl estradiol;ethinyl estradiol | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | QUARTETTE | 7/10/2013 |
levonorgestrel;ethinyl estradiol;ethinyl estradiol | Tablets | 0.1 mg/0.02 mg and 0.01 mg | LOSEASONIQUE | 11/16/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.3 mg, 0.45 mg and 0.9 mg | CENESTIN | 3/19/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.625 mg | CENESTIN | 3/2/2009 |
conjugated estrogen (synthetic a) | Tablets | 1.25 mg | CENESTIN | 11/3/2008 |
levonorgestrel; ethinyl estradiol; ethinyl estradiol | Tablets | 0.15 mg/0.03 mg/0.01 mg | SEASONIQUE | 1/22/2008 |
levonorgestrel and ethinyl estradiol | Tablets | 0.15 mg/0.03 mg | SEASONALE | 3/29/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,743,413 | Suspension aerosol formulations | ► Subscribe | |||||||||||||||||||||||||||
| 6,250,127 | Heat-dissipating aluminum silicon carbide composite manufacturing method | ► Subscribe | |||||||||||||||||||||||||||
| 7,749,989 | Estrogenic compounds, methods of using and methods of administering the same | ► Subscribe | |||||||||||||||||||||||||||
| 9,108,010 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 7,772,219 | Methods of hormonal treatment utilizing extended cycle contraceptive regimens | ► Subscribe | |||||||||||||||||||||||||||
| 7,459,445 | Estrogenic compounds and topical pharmaceutical formulations of the same | ► Subscribe | |||||||||||||||||||||||||||
| 7,101,534 | Suspension aerosol formulations | ► Subscribe | |||||||||||||||||||||||||||
| 9,533,111 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 9,737,674 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 7,179,799 | (3) and (6) substituted estrogenic compounds | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Denmark | 2692341 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1117140 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2532089 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 4897570 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5888645 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2011256181 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2014128709 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5970037 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1758631 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1115748 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 00017 | Denmark | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 | ||||||||||||||||||||||||||
| 0160011 00192 | Estonia | ► Subscribe | PRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015 | ||||||||||||||||||||||||||
| 156 | Luxembourg | ► Subscribe | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 | ||||||||||||||||||||||||||
| 0814 | Netherlands | ► Subscribe | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 | ||||||||||||||||||||||||||
| 00221 | Netherlands | ► Subscribe | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 | ||||||||||||||||||||||||||
| 2015000093 | Germany | ► Subscribe | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 | ||||||||||||||||||||||||||
| 2016 00016 | Denmark | ► Subscribe | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 | ||||||||||||||||||||||||||
| 2006 00038 | Denmark | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 | ||||||||||||||||||||||||||
| /2015 | Austria | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211 | ||||||||||||||||||||||||||
| 00C/027 | Belgium | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,728 others who get our Drug Patent Expiration Alerts:
